SageView Advisory Group LLC Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

SageView Advisory Group LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 4th quarter, HoldingsChannel reports. The firm owned 7,177 shares of the biopharmaceutical company’s stock after selling 369 shares during the period. SageView Advisory Group LLC’s holdings in Gilead Sciences were worth $663,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 2.8 %

Shares of GILD opened at $106.50 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $132.61 billion, a price-to-earnings ratio of 287.84, a PEG ratio of 0.71 and a beta of 0.32. The firm’s 50-day moving average price is $108.48 and its 200-day moving average price is $97.05. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.97%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GILD shares. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Oppenheimer lifted their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. Royal Bank of Canada increased their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Bank of America boosted their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.